[go: up one dir, main page]

EP1030666A1 - Novel use of compounds for anti-pruritic activity - Google Patents

Novel use of compounds for anti-pruritic activity

Info

Publication number
EP1030666A1
EP1030666A1 EP98953608A EP98953608A EP1030666A1 EP 1030666 A1 EP1030666 A1 EP 1030666A1 EP 98953608 A EP98953608 A EP 98953608A EP 98953608 A EP98953608 A EP 98953608A EP 1030666 A1 EP1030666 A1 EP 1030666A1
Authority
EP
European Patent Office
Prior art keywords
compound
xxaanntthhiinnee
bbuuttyyll
group
aammiinnoo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98953608A
Other languages
German (de)
French (fr)
Other versions
EP1030666A4 (en
Inventor
Don E. Griswold
Siegfried Benjamin Christensen, Iv
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP1030666A1 publication Critical patent/EP1030666A1/en
Publication of EP1030666A4 publication Critical patent/EP1030666A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Definitions

  • the present invention relates to compounds which are of use in the treatment and management of pruritis.
  • Pruritis is a common symptom of many inflammatory skin diseases, notably psoriasis and atopic dermatitis. This symptom has historically been difficult to model. Recently, a behavioral model for peripherally evoked itch was published (Woodward et al., Characterization of a behavioral model for peripherally evoked itch suggests platelet-activating factor as a potent pruritogen. J. Pharmacol. Exp. Therap. 272:758- 765, 1995). This model has lead to additional modifications as will be shown herein. As little effective treatment for this condition exists, there remains a need for treatment, in this field, for compounds which are capable of anti-pruritic activity.
  • This invention relates to the novel use of PDE4 inhibitors, preferably compounds of Formula (I) for the prophylaxis, treatment and management of pruritis in a mammal, including humans, in need of such treatment, which method comprises administering to such mammal, an effective amount of a compound of Formula (I).
  • PDE4 inhibitors preferably compounds of Formula (I) for the prophylaxis, treatment and management of pruritis in a mammal, including humans, in need of such treatment, which method comprises administering to such mammal, an effective amount of a compound of Formula (I).
  • the compounds of the present invention of Formula (I) are described herein.
  • Figure I demonstrates the anti-pruritic activity of compound I. 1 ,3-di- cyclopropylmethyl-8-amino xanthine in an arachidonic acid induced pruritis model.
  • PDE4 inhibitors as a class of compounds, regardless of structure possess anti-pruritis activity As pruritis is a key symptom of many different disease states, the use of PDE4 inhibitors in the managment of pruritic activity is of great value. While it is recognized that PDE4 compounds are of many different structural classes, they all share a common feature, inhibition of the PDE4 isoenzymes.
  • PDE4 compounds for use herein include, but are not limited to, those desc ⁇ bed in WO 92/00968, PCT/US91/08229, WO 92/05175, WO 92/05176, WO 92/11260, WO 93/01014, PCT/US92/03613, WO 93/07111, PCT/US93/02045, WO 93/19748, WO 93/19750, WO 93/19751, WO 93/19747, WO 93/19749, WO 93/19720, WO 94/20079, WO 95/00139, WO 95/08581, WO 95/09308, WO 95/09623, WO 95/09836, WO 95/09624, WO 95/09837, WO 95/0
  • CP 80633 is describ-sd in J.M. Hanifin et al. J. Invest. Dermatol. 107:51-56 (1996).
  • the method of use does net include the compound CP80633.
  • the compounds of Formula (I) may also be used in association with the vete ⁇ nary treatment of mammals, other than in humans, in need of such treatment for pruritis Treatment, may be therapeutically or prophylactically in animals
  • Patent 5,734,05 1 are represented by the structure
  • Rl and R 2 are each independently alkyl or a moiety of the formula -(CH 2 ) m -A, m is a number from 0 to 3, A is an unsubstituted or substituted cyclic hydrocarbon radical R3 is halogen, nitro, or -NR 4 R 5 ;
  • R4 and R 5 are independently hydrogen, alkyl, alkylcarbonyl or together with the nitrogen to which they are attached forming an optionally substituted heterocyclic ring; and the pharmaceutically acceptable salts thereof.
  • both Ri and R2 represent -(CH2) m -A.
  • the A moiety represents a C 3 -8 cycloalkyl group, particularly a C3- 6 cycloalkyl and preferably unsubstituted. More preferably A is a cyclopropyl or cyclobutyl moiety.
  • m is zero or one.
  • Suitable optional substituent groups for any cyclic hydrocarbon include a Ci ⁇ alkyl moiety or halogen atom.
  • a preferred group for Ri or R 2 is an alkyl group of 1 to 6 carbons, specifically methyl, ethyl, propyl or n-butyl. More preferred is n-butyl.
  • R 3 is halogen
  • the preferred substitution is bromine or chlorine
  • R3 is -NR 4 R 5
  • R 4 and R5 represent alkyl or alkylcarbonyl
  • one of R4 or R 5 is hydrogen
  • Suitable heterocyclic groups include saturated or unsaturated heterocylic groups having single or fused rings, each ring having 5 to 7 ring atoms which ring atoms optionally comprise up to two additional hetero atoms selected from 0, N, or S.
  • Preferred heterocyclic groups include single rings comprising 5 to 7 ring atoms, more preferably 5 to 6 ring atoms,and most preferably 6 ring atoms
  • Preferred heterocyclic groups are pyrrolidinyl, piperidinyl, or morpholinyl rings
  • 1,3-d n-butyl-8-nitro xanthine 1,3-d •cyclopropylmethyl-8-nitro xanthine, 1,3-d cyclobutylmethyl-8-nitro xanthine; 1,3-d cyclopentylmethyl-8-nitro xanthine; 1,3-d cyclohexylmethyl-8-nitro xanthine, 1,3-d n-butyl-8-amino xanthine; 1,3-d -cyclopropylmethyl-8-amino xanthine, 1,3-d -cyclobutylmethyl-8-amino xanthine, 1,3-d -cyclopentylmethyl-8-amino xanthine; 1,3-d -cyclohexylmethyl-8-amino xanthine, 1,3-d: -cyclopropyl-8-amino xanthine; 1,3-d -n-butyl-8-acetamido
  • the most preferred compound of Formula (I) for use in the method of this invention is l,3-di-cyclopropylmethyl-8-amino xanthine or a pharmaceutically acceptable salt thereof.
  • alkyl groups as used herein alone or when used as part of another group (for example as in alkylcarbonyl) is meant to include both straight or branched chain radicals of 1 to 12 carbon atoms, unless the chain length is limited thereto, including, but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec- butyl, isobutyl, tert-butyl, and the like.
  • cyclic hydrocarbon unless specified otherwise, as used herein is meant a single ring or a fused rings of 3 to 8 carbon atoms. Cyclic hydrocarbons may comprise up to 8 carbons in each ring.
  • cycloalkyl or “cycloalkyl alkyl” as used herein is meant to be interchangeable with the term “cyclic hydrocarbon”
  • Cycloalkyl and cycloalkyl-alkyl groups are meant to include, but not limited to cyclopropyl, cyclopropyl-methyl, cyclopentyl or cyclohexyl.
  • halo as used herein is meant all halogens, i.e.. chloro, fluoro, bromo and iodo.
  • the compounds of Formula (I) or a pharmaceutically acceptable salt thereof can also be used in the manufacture of a medicament for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by excessive or or unregulated pruritic activity.
  • the compounds of Formula (I) may be used topically in the treatment or prophylaxis of topical disease states which have a pruritic component.
  • the compounds of Formula (I) are disclosed in Maschler et al.. Great Britain Patent Application No. 8906792.0 filed on March 23, 1989, and US Patent 5,734,051 for the treatment of disorders associated with increased numbers of eosinophils, such as proliferative skin disease states, i.e. psoriasis, atopic dermatitis, non-specific dermititis, primary irritant contact dermatitis, allergic contact dermititis, or allergic disorders such as atopy, uticaria, eczema, rhinitis, serborrheic dermatitis, and mange in domestic animals.
  • proliferative skin disease states i.e. psoriasis, atopic dermatitis, non-specific dermititis, primary irritant contact dermatitis, allergic contact dermititis, or allergic disorders such as atopy, uticaria, eczema, rhinitis, serborrheic dermatiti
  • the compounds of Formula (I) are also disclosed in PCT/US91/08734, and PCT US93/01496 published as WO 93/06699 whose dislosures are incorporated herein by reference in its entirety, for the treatment of tumour necrosis mediated diseases.
  • the compounds of Formula (I) may, be administered concurrently with another agents useful for the treatment or managment of pruritis, such as steroids.
  • a monokine activity interfering agent required for therapeutic effect will, of course, vary with the agent chosen, the route of administration desired, the nature and severity of the disease, and the particular condition of the mammal, specifically human, undergoing treatment, and is ultimately at the discretion of the physician. It will also be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of the agent will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques.
  • the optimal course of treatment i.e., the number of doses of the agent given per day for a defined number of days
  • the compounds of Formula (I) may be administered orally (when active by this route), topically, parenterally or by inhalation in conventional dosage forms prepared by combining such agent with standard pharmaceutical earners according to conventional procedures in an amount sufficient to produce therapeutic activity
  • the pharmaceutical earner employed can be readily determined by one of skill in the art who will recognize that such determination will depend upon vanous well- known factors such as the nature, quantity and character of the particular monokine activity mterfenng agent being employed and the form and route of administration desired
  • the earners employed may be those desenbed elsewhere herein
  • the pharmaceutical composition of the present invention will comprise an effective, non-toxic amount of a compound of Formula (I) and a pharmaceutically acceptable earner or diluent
  • the compounds of Formula (I) are administered in conventional dosage forms prepared by combining a compound of Formula (I) in an amount sufficient to produce activity, respectively, with standard pharmaceutical earners according to conventional procedures These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropnate to the desired preparation
  • the pharmaceutical earner employed may be, for example either a solid or liquid Exemplary of solid earners are lactose, terra alba, sucrose talc, gelatin, agar pectin, acacia, magnesium stearate, steanc acid and the like Exemplary of liquid earners are syrup, peanut oil, olive oil, polyethylene glycol, coconut oil, water and the like
  • the earner or diluent may include time delay mate ⁇ al well known to the art such as glyceryl monostearate or glyceryl di
  • compositions of Formula (I) and their pharmaceutically acceptable salts can be employed in a wide vanety of pharmaceutical forms
  • the preparation of a pharmaceutically acceptable salt will be determined by the nature of the compound itself, and can be prepared by conventional techniques readily available to one skilled in the art
  • a solid earner if a solid earner is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge
  • the amount of solid earner will vary widely but preferably will be from about 25 mg to about 1 gram
  • the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, stenle injectable liquid such as an ampule or nonaqueous liquid suspension
  • any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell.
  • composition is in the form of a soft gelatin shell capsule
  • any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils and are incorporated in a soft gelatin capsule shell
  • a syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, polyethylene glycol, coconut oil, glycerine or water with a flavouring or colouring agent.
  • the amount of a compound of Formula (I) required for therapeutic effect on topical administration will, of course, vary with the compound chosen, the nature and severity of the inflammatory condition and the animal undergoing treatment, and is ultimately at the discretion of the physician.
  • parenteral' as used herein includes intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration
  • the subcutaneous and intramuscular forms of parenteral administration are generally preferred. Appropriate dosage forms for such administration may be prepared by conventional techniques.
  • Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil, for example polyethylene glycol, polyviny'pyrrolido ⁇ c, lecithin, arachis oil, or sesame oil
  • a parenterally acceptable oil for example polyethylene glycol, polyviny'pyrrolido ⁇ c, lecithin, arachis oil, or sesame oil
  • the daily dosage regimen for parenteral administration is suitably about 0 001 mg/Kg to 40 mg/Kg, preferably about 0 01 mg/Kg to 20 mg/Kg, of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base
  • the compounds of Formula (I) may be administered orally
  • the daily dosage regimen for oral administration is suitably about 1 mg/kg to 1 OOOmg day
  • the dosage is suitably about 001 mg/kg to 40mg/kg, preferably about 0 01 to 20 mg/Kg of a compound of formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base
  • the active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit activity
  • the compounds of Formula (I) may also be administered by inhalation
  • inhalation is meant intranasal and oral inhalation administration
  • Appropriate dosage forms for such administration such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques.
  • the daily dosage regimen for inhalation administration is suitably about 001 mg/kg to 40mg/kg, preferably 0 01 to 20 mg/Kg of a compound of formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base
  • Typical compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or t ⁇ chlorofluoromethane
  • the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to himself a single dose
  • the compounds of Formula (I) may also be administered topically
  • Bv topical administration is meant non-systemic administration and includes the application of a
  • systemic administration oral, intravenous, intrapentoneal and intramuscular administration
  • the active ingredient may compnse, for topical administration, from 0 001% to 10% w/w e g from 1% to 2% by weight of the formulation although it may compnse as m u ch as 10% w/w but preferably not in excess of 5% w/w and more preferably from 0 1% to 1% w/w of the formulation
  • the topical formulations of the present invention comprise an active ingredient together with one or more acceptable carner(s) therefor and optionally any other therapeutic ⁇ ngred ⁇ ent(s)
  • the car ⁇ er(s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deletenous to the recipient thereof
  • Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose
  • Drops according to the present invention may comprise ste ⁇ le aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactencidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent
  • the resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and ste ⁇ lized by autoclaving or maintaining at 98-100°C for half an hour
  • the solution may be sten zed by filtration and transfened to the container by an aseptic technique
  • bactencidal and fungicidal agents suitable for inclusion in the drops are phenylmercu ⁇ c nitrate or acetate (0 002%), benzalkonium chlonde (0 01%) and chlorhexidme acetate (0 01%)
  • Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol
  • Lotions according to the present invention include those suitable for application to the skin or eye
  • An eye lotion may compnse a stenle aqueous solution optionally containing a bactencide and may be prepared by methods similar to those for the preparation of drops
  • Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moistu ⁇ zer such as glycerol or an oil such as castor oil or arachis oil
  • Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application
  • Thev may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery with a greasy or non-greasy basis
  • the basis may compnse hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap, a mucilage, an oil of natural o ⁇ gm such as almond, corn, arachis, castor or olive oil, wool fat or its denvatives, or a fatty acid such as stenc or oleic acid together with an alcohol such as propylene glycol or macrogols
  • the formulation may incorporate any suitable surface active agent such as an anionic, catiomc or non-ionic surfactants such as sorbitan esters or polyoxyethylene denvatives thereof Suspending agents
  • the form and character of the pharmaceutically acceptable earner or diluent is dictated by the amount of active ingredient, a compound of Formula (I), with which it is to be combined, the route of administration and other well-known vanables
  • the optimal quantity and spacing of individual dosages of a compound of Formula (I) or a pharmaceutically acceptable salt thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration and the particular patient being treated, and that such optimums can be determined by conventional techniques
  • the optimal course of treatment 1 e the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
  • Formulations for pharmaceutical use incorporating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of liquid formulations are given below.
  • a solution containing a compound of Formula (I) is prepared by dissolving the compound in water, or other suitable carrier, with or without a preservative, such as benzoic acid, to deliver the desired amount of drug per use
  • the compound is present in an amount from about lO ⁇ g to about 30 ⁇ g/ per ml of carrier
  • a solution containing a compound of Formula (I) is prepared by dissolving the compound in an amount from about 1 to about lOmg per ml of PEG 400 with or without BHA/BHT preservatives
  • the solution can alternatively be filled into a soft gelatin capsule to prepare a solid oral dosage form or used as a syrup
  • a solid dosage form containing a compound of Formula (I), such as 1,3-di- cyclopropylmethyl-8-amino xanthine has been prepared by mixing 50mg of the compound with various concentration (mg) of mannitol, hydroxypropylmethylcellulose, calipharm, Starch 1500, and magnesium sterate (as a lubricant), to fill capsules of an appropriate size or the composition may, if desired, be compressed into tablets
  • a compound of Formula (I) such as 1,3-di- cyclopropylmethyl-8-amino xanthine
  • the mouse model takes advantage of the cutaneous inflammatory response to arachidonic acid which is preceeded by scratching and rubbing behavior indicative of pruritis.
  • mice were administered a topical dose of arachidonic acid (2 mg/ear) in 20 ul cold acetone to the left ear.
  • the treated mice were then placed individually into 4L beakers. After a 2 min accommodation period, the episodes of scratching and head shaking were counted over a 10 min period.
  • the data were analysed by calculating the mean and standard error. A statistical difference in the mean values was determined using Student's t-test.
  • the biochemical pharmacology of the inflammatory response to arachidonic acid has implicated mast cell degranulation and eicosanoid inflammatory mediator release (e.g. leukotrienes and prostanoids). Tachykinins and platelet activating factor may also be involved in this response.
  • PDE4 phosphodiesterase type 4
  • BRL 61063 is the same as Compound I.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Derivatives of 8-substituted xanthines which are used in the prophylactic or therapy of diseases or disorders which have a pruritic component.

Description

NOVEL USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY
FIELD OF INVENTION
The present invention relates to compounds which are of use in the treatment and management of pruritis.
BACKGROUND OF THE INVENTION Pruritis is a common symptom of many inflammatory skin diseases, notably psoriasis and atopic dermatitis. This symptom has historically been difficult to model. Recently, a behavioral model for peripherally evoked itch was published (Woodward et al., Characterization of a behavioral model for peripherally evoked itch suggests platelet-activating factor as a potent pruritogen. J. Pharmacol. Exp. Therap. 272:758- 765, 1995). This model has lead to additional modifications as will be shown herein. As little effective treatment for this condition exists, there remains a need for treatment, in this field, for compounds which are capable of anti-pruritic activity.
SUMMARY OF THE INVENTION This invention relates to the novel use of PDE4 inhibitors, preferably compounds of Formula (I) for the prophylaxis, treatment and management of pruritis in a mammal, including humans, in need of such treatment, which method comprises administering to such mammal, an effective amount of a compound of Formula (I). The compounds of the present invention of Formula (I) are described herein.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure I demonstrates the anti-pruritic activity of compound I. 1 ,3-di- cyclopropylmethyl-8-amino xanthine in an arachidonic acid induced pruritis model.
DETAILED DESCRIPTION OF THE INVENTION
The present invention has found that PDE4 inhibitors, as a class of compounds, regardless of structure possess anti-pruritis activity As pruritis is a key symptom of many different disease states, the use of PDE4 inhibitors in the managment of pruritic activity is of great value. While it is recognized that PDE4 compounds are of many different structural classes, they all share a common feature, inhibition of the PDE4 isoenzymes. A skilled .artisan, using well known and defined assays, will be able to determine if a compound is an inhibitor of the PDE4 isoenzymes, and be of use herein Suitable PDE4 compounds for use herein include, but are not limited to, those descπbed in WO 92/00968, PCT/US91/08229, WO 92/05175, WO 92/05176, WO 92/11260, WO 93/01014, PCT/US92/03613, WO 93/07111, PCT/US93/02045, WO 93/19748, WO 93/19750, WO 93/19751, WO 93/19747, WO 93/19749, WO 93/19720, WO 94/20079, WO 95/00139, WO 95/08581, WO 95/09308, WO 95/09623, WO 95/09836, WO 95/09624, WO 95/09837, WO 95/09627, WO 95/24381, WO 95/27692, WO 96/19995, WO 96/20158, WO 96/20153, WO 96/19980, WO 96/19988, WO96/19977, WO 96/20161, WO 96/20157, PCT/US95/16707, WO 96/20690, WO 96/20159, WO 96/19983, WO 96/19984, WO 96/19985, WO 96/19990, WO 96/19994, WO 96/20163, WO 96/20156, WO 96/19986, WO 96/20174, WO 96/19979, WO 96/20160 WO 96/20175, WO 96/19993, WO 96/20162, WO 96/19978, WO 96/23754, WO 96/36594, , WO 97/03945, US 5,734,051 and US 5,420, 154 Suitable assays for determination of PDE4 activity are also described in the above noted references, whose disclosures are incorporated by reference herein in their entirety
A particular PDE4, CP 80633 is describ-sd in J.M. Hanifin et al. J. Invest. Dermatol. 107:51-56 (1996). Preferably, the method of use does net include the compound CP80633.
The compounds of Formula (I) may also be used in association with the veteπnary treatment of mammals, other than in humans, in need of such treatment for pruritis Treatment, may be therapeutically or prophylactically in animals
The compounds of the present invention of Formula (I), are descπbed in US
Patent 5,734,05 1 and are represented by the structure
wherein
Rl and R2 are each independently alkyl or a moiety of the formula -(CH2)m-A, m is a number from 0 to 3, A is an unsubstituted or substituted cyclic hydrocarbon radical R3 is halogen, nitro, or -NR4R5;
R4 and R5 are independently hydrogen, alkyl, alkylcarbonyl or together with the nitrogen to which they are attached forming an optionally substituted heterocyclic ring; and the pharmaceutically acceptable salts thereof.
Preferably both Ri and R2 represent -(CH2)m-A. Preferably the A moiety represents a C3-8 cycloalkyl group, particularly a C3-6 cycloalkyl and preferably unsubstituted. More preferably A is a cyclopropyl or cyclobutyl moiety. Preferably m is zero or one. Suitable optional substituent groups for any cyclic hydrocarbon include a Ci^alkyl moiety or halogen atom.
A preferred group for Ri or R2 is an alkyl group of 1 to 6 carbons, specifically methyl, ethyl, propyl or n-butyl. More preferred is n-butyl.
When R3 is halogen, the preferred substitution is bromine or chlorine
When R3 is -NR4R5, and R4 and R5 represent alkyl or alkylcarbonyl, it is preferred that one of R4 or R5 is hydrogen
Suitable heterocyclic groups include saturated or unsaturated heterocylic groups having single or fused rings, each ring having 5 to 7 ring atoms which ring atoms optionally comprise up to two additional hetero atoms selected from 0, N, or S. Preferred heterocyclic groups include single rings comprising 5 to 7 ring atoms, more preferably 5 to 6 ring atoms,and most preferably 6 ring atoms Preferred heterocyclic groups are pyrrolidinyl, piperidinyl, or morpholinyl rings
Specifically exemplified compounds of Formula (I) are
1,3-d n-butyl-8-nitro xanthine; 1,3-d •cyclopropylmethyl-8-nitro xanthine, 1,3-d cyclobutylmethyl-8-nitro xanthine; 1,3-d cyclopentylmethyl-8-nitro xanthine; 1,3-d cyclohexylmethyl-8-nitro xanthine, 1,3-d n-butyl-8-amino xanthine; 1,3-d -cyclopropylmethyl-8-amino xanthine, 1,3-d -cyclobutylmethyl-8-amino xanthine, 1,3-d -cyclopentylmethyl-8-amino xanthine; 1,3-d -cyclohexylmethyl-8-amino xanthine, 1,3-d: -cyclopropyl-8-amino xanthine; 1,3-d -n-butyl-8-acetamido xanthine,
- j 1,3-d n-butyl-8-chloro xanthine; 1,3-d -n-butyl-8-bromo xanthine; 1,3-d cyclopropylmethyl-8-chloro xanthine; 1,3-d cyclohexyl-8-chloro xanthine; 1,3-d n-butyl-8-piperidino xanthine; 1,3-d -cyclopropylmethyl-8-morpholino xanthine; 1,3-d -n-butyl-8-pyrrolidinyl xanthine; 1,3-d -cyclopropylmethyl-8-pyrrolidinyl xanthine; 1,3-d: cyclopropylmethyl-8-piperidinyl xanthine; 1,3-d -cyclohexylmethyl-8-piperidinyl xanthine; 1,3-d cyclohexylmethyl-8-bromo xanthine; and 1,3-d cyclohexyl-8-nitro xanthine; or the pharmaceutically acceptable salts thereof.
The most preferred compound of Formula (I) for use in the method of this invention is l,3-di-cyclopropylmethyl-8-amino xanthine or a pharmaceutically acceptable salt thereof.
By the term "alkyl" groups as used herein, alone or when used as part of another group (for example as in alkylcarbonyl) is meant to include both straight or branched chain radicals of 1 to 12 carbon atoms, unless the chain length is limited thereto, including, but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec- butyl, isobutyl, tert-butyl, and the like.
By the term "cyclic hydrocarbon", unless specified otherwise, as used herein is meant a single ring or a fused rings of 3 to 8 carbon atoms. Cyclic hydrocarbons may comprise up to 8 carbons in each ring. The term "cycloalkyl" or "cycloalkyl alkyl" as used herein is meant to be interchangeable with the term "cyclic hydrocarbon" Cycloalkyl and cycloalkyl-alkyl groups are meant to include, but not limited to cyclopropyl, cyclopropyl-methyl, cyclopentyl or cyclohexyl.
By the term "halo" as used herein is meant all halogens, i.e.. chloro, fluoro, bromo and iodo.
METHODS OF PREPARATION
The preparation of the compounds of Formula (I) can be carried out by one of skill in the art according to the procedures outlined herein, and as described in Maschler et al.. Great Britain Patent Application No. 8906792.0 filed on March 23, 1989, and US Patent No. 5,734,051 whose entire disclosures are incorporated herein by reference in its entirety.
METHODS OF TREATMENT The compounds of Formula (I) or a pharmaceutically acceptable salt thereof can also be used in the manufacture of a medicament for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by excessive or or unregulated pruritic activity.
The compounds of Formula (I) may be used topically in the treatment or prophylaxis of topical disease states which have a pruritic component.
The compounds of Formula (I) are disclosed in Maschler et al.. Great Britain Patent Application No. 8906792.0 filed on March 23, 1989, and US Patent 5,734,051 for the treatment of disorders associated with increased numbers of eosinophils, such as proliferative skin disease states, i.e. psoriasis, atopic dermatitis, non-specific dermititis, primary irritant contact dermatitis, allergic contact dermititis, or allergic disorders such as atopy, uticaria, eczema, rhinitis, serborrheic dermatitis, and mange in domestic animals. The compounds of Formula (I) are also disclosed in PCT/US91/08734, and PCT US93/01496 published as WO 93/06699 whose dislosures are incorporated herein by reference in its entirety, for the treatment of tumour necrosis mediated diseases. The compounds of Formula (I) may, be administered concurrently with another agents useful for the treatment or managment of pruritis, such as steroids.
It will be recognized by one of skill in the art that the actual amount of a monokine activity interfering agent required for therapeutic effect will, of course, vary with the agent chosen, the route of administration desired, the nature and severity of the disease, and the particular condition of the mammal, specifically human, undergoing treatment, and is ultimately at the discretion of the physician. It will also be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of the agent will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of the agent given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests. The compounds of Formula (I) may be administered orally (when active by this route), topically, parenterally or by inhalation in conventional dosage forms prepared by combining such agent with standard pharmaceutical earners according to conventional procedures in an amount sufficient to produce therapeutic activity
The pharmaceutical earner employed can be readily determined by one of skill in the art who will recognize that such determination will depend upon vanous well- known factors such as the nature, quantity and character of the particular monokine activity mterfenng agent being employed and the form and route of administration desired The earners employed may be those desenbed elsewhere herein
In order to use a compound of the Formula (I) or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition
The pharmaceutical composition of the present invention will comprise an effective, non-toxic amount of a compound of Formula (I) and a pharmaceutically acceptable earner or diluent The compounds of Formula (I) are administered in conventional dosage forms prepared by combining a compound of Formula (I) in an amount sufficient to produce activity, respectively, with standard pharmaceutical earners according to conventional procedures These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropnate to the desired preparation The pharmaceutical earner employed may be, for example either a solid or liquid Exemplary of solid earners are lactose, terra alba, sucrose talc, gelatin, agar pectin, acacia, magnesium stearate, steanc acid and the like Exemplary of liquid earners are syrup, peanut oil, olive oil, polyethylene glycol, coconut oil, water and the like Similarly, the earner or diluent may include time delay mateπal well known to the art such as glyceryl monostearate or glyceryl distearate alone or with a wax
Compounds of Formula (I) and their pharmaceutically acceptable salts can be employed in a wide vanety of pharmaceutical forms The preparation of a pharmaceutically acceptable salt will be determined by the nature of the compound itself, and can be prepared by conventional techniques readily available to one skilled in the art Thus, if a solid earner is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge The amount of solid earner will vary widely but preferably will be from about 25 mg to about 1 gram When a liquid earner is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, stenle injectable liquid such as an ampule or nonaqueous liquid suspension Where the composition is in the form of a capsule, any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell. Where the composition is in the form of a soft gelatin shell capsule any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils and are incorporated in a soft gelatin capsule shell A syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, polyethylene glycol, coconut oil, glycerine or water with a flavouring or colouring agent.
The amount of a compound of Formula (I) required for therapeutic effect on topical administration will, of course, vary with the compound chosen, the nature and severity of the inflammatory condition and the animal undergoing treatment, and is ultimately at the discretion of the physician.
The term 'parenteral' as used herein includes intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration The subcutaneous and intramuscular forms of parenteral administration are generally preferred. Appropriate dosage forms for such administration may be prepared by conventional techniques.
Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil, for example polyethylene glycol, polyviny'pyrrolidoπc, lecithin, arachis oil, or sesame oil The daily dosage regimen for parenteral administration is suitably about 0 001 mg/Kg to 40 mg/Kg, preferably about 0 01 mg/Kg to 20 mg/Kg, of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base
The compounds of Formula (I) may be administered orally The daily dosage regimen for oral administration is suitably about 1 mg/kg to 1 OOOmg day For administration the dosage is suitably about 001 mg/kg to 40mg/kg, preferably about 0 01 to 20 mg/Kg of a compound of formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base The active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit activity The compounds of Formula (I) may also be administered by inhalation By
"inhalation" is meant intranasal and oral inhalation administration Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques. The daily dosage regimen for inhalation administration is suitably about 001 mg/kg to 40mg/kg, preferably 0 01 to 20 mg/Kg of a compound of formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base Typical compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or tπchlorofluoromethane Preferably the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to himself a single dose The compounds of Formula (I) may also be administered topically Bv topical administration is meant non-systemic administration and includes the application of a compound of Formula (I) externally to the epidermis, to the buccal cavity and instillation of such a compound into the ear, eye and nose, and where the compound does not significantly enter the blood stream The daily dosage regimen for topical administration is suitably about 001 mg/kg to lOOmg/kg, preferably 0 1 to 20 mg/Kg of a compound of formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base
By systemic administration is meant oral, intravenous, intrapentoneal and intramuscular administration
While it is possible for an active ingredient to be administered alone as the raw chemical, it is preferable to present it as a pharmaceutical formulation The active ingredient may compnse, for topical administration, from 0 001% to 10% w/w e g from 1% to 2% by weight of the formulation although it may compnse as much as 10% w/w but preferably not in excess of 5% w/w and more preferably from 0 1% to 1% w/w of the formulation
The topical formulations of the present invention comprise an active ingredient together with one or more acceptable carner(s) therefor and optionally any other therapeutic ιngredιent(s) The carπer(s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deletenous to the recipient thereof
Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose
Drops according to the present invention may comprise steπle aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactencidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and steπlized by autoclaving or maintaining at 98-100°C for half an hour Alternatively, the solution may be sten zed by filtration and transfened to the container by an aseptic technique Examples of bactencidal and fungicidal agents suitable for inclusion in the drops are phenylmercuπc nitrate or acetate (0 002%), benzalkonium chlonde (0 01%) and chlorhexidme acetate (0 01%) Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol
Lotions according to the present invention include those suitable for application to the skin or eye An eye lotion may compnse a stenle aqueous solution optionally containing a bactencide and may be prepared by methods similar to those for the preparation of drops Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moistuπzer such as glycerol or an oil such as castor oil or arachis oil
Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application Thev may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery with a greasy or non-greasy basis The basis may compnse hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap, a mucilage, an oil of natural oπgm such as almond, corn, arachis, castor or olive oil, wool fat or its denvatives, or a fatty acid such as stenc or oleic acid together with an alcohol such as propylene glycol or macrogols The formulation may incorporate any suitable surface active agent such as an anionic, catiomc or non-ionic surfactants such as sorbitan esters or polyoxyethylene denvatives thereof Suspending agents such as natural gums cellulose derivatives or inorganic materials such as silicaceous silicas and other ingredients such as lanolin, may also be included
It will be recognized by one of skill in the art that the form and character of the pharmaceutically acceptable earner or diluent is dictated by the amount of active ingredient, a compound of Formula (I), with which it is to be combined, the route of administration and other well-known vanables It will be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of Formula (I) or a pharmaceutically acceptable salt thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration and the particular patient being treated, and that such optimums can be determined by conventional techniques It will also be appreciated by one of skill in the art that the optimal course of treatment 1 e the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
FORMULATION EXAMPLES Formulations for pharmaceutical use incorporating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of liquid formulations are given below.
1 A solution containing a compound of Formula (I) is prepared by dissolving the compound in water, or other suitable carrier, with or without a preservative, such as benzoic acid, to deliver the desired amount of drug per use The compound is present in an amount from about lOμg to about 30 μg/ per ml of carrier
2 A solution containing a compound of Formula (I) is prepared by dissolving the compound in an amount from about 1 to about lOmg per ml of PEG 400 with or without BHA/BHT preservatives The solution can alternatively be filled into a soft gelatin capsule to prepare a solid oral dosage form or used as a syrup
3 A solid dosage form containing a compound of Formula (I), such as 1,3-di- cyclopropylmethyl-8-amino xanthine has been prepared by mixing 50mg of the compound with various concentration (mg) of mannitol, hydroxypropylmethylcellulose, calipharm, Starch 1500, and magnesium sterate (as a lubricant), to fill capsules of an appropriate size or the composition may, if desired, be compressed into tablets Various formulation of the ingredients are presented in Table 1 , numbered from 1 to 6
UTILITY EXAMPLES
The method described in the Woodward et al manuscript, supra, served as the protoype for the mouse model which developed in the present invention The mouse model takes advantage of the cutaneous inflammatory response to arachidonic acid which is preceeded by scratching and rubbing behavior indicative of pruritis..
Briefly. Balb/c mice were administered a topical dose of arachidonic acid (2 mg/ear) in 20 ul cold acetone to the left ear. The treated mice were then placed individually into 4L beakers. After a 2 min accommodation period, the episodes of scratching and head shaking were counted over a 10 min period. The data were analysed by calculating the mean and standard error. A statistical difference in the mean values was determined using Student's t-test. The biochemical pharmacology of the inflammatory response to arachidonic acid has implicated mast cell degranulation and eicosanoid inflammatory mediator release (e.g. leukotrienes and prostanoids). Tachykinins and platelet activating factor may also be involved in this response. The anti-inflammatory activity of phosphodiesterase type 4 (PDE4) inhibitors was also demonstrated using arachidonic acid (Griswold, D.E.et al., Pharmacology of the pyrroloimidazole, SK&F 105809. Antiinflammatoiy activity and inhibition of mediator production in vivo. Biochemical Pharmacology 42:825-831, 1991) whose disclosure is incorporated by reference herein in its entirety.
Specific Methods:
Male Balb/c mice (n=6/treatment group) weighing 19-23 grams were administered a topical dose of arachidonic acid (2 mg/ear) in 20 ul cold acetone to the left ear. Immediately after that application, vehicle or test compound was applied to the same ear in a volume of 25 ul. Doses varied from 5 to 1000 ug/ear. The treated mice were then placed individually into 4L beakers. After a 2 min accommodation period, the episodes of scratching and head shaking were counted over a 10 min period. The data were analysed by calculating the mean and standard error. A statistical difference in the mean values was determin-ed using Student's t-test.
It was of interest, therefore to determine if PDE4 inhibitors of different structural classes would demonstrate anti-pruritic activity in this model. As indicated below, three such PDE4 inhibitors did demonstrate signficant anti-pruritic activity.
Topical Anti- ruritic Acitivit of PDE4 Inhibitors
***, Statistically significant at a p < 0.001 versus vehicle control, BRL 61063 is the same as Compound I.
All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.
The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further elaboration, it is believed that one skilled in the are can, using the preceding description, utilize the present invention to its fullest extent. Therefore the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.

Claims

What is Claimed is
1. A method of treating pruritis in a mammal in need thereof which comprises administering to such mammal an effective amount of a compound of a PDE4 inhibitor, other than CP 80633.
2. The method according to Claim 1 wherein the PDE4 inhibitor is a compound of the formula:
wherein Ri and R2 each independently represent alkyl or -(CH2) - A; m represents zero or an integer 1, 2 or 3;
A represents a substituted or unsubstituted cyclic hydrocarbon radical; R3 represents a halogen atom, a nitro group, or a group -NR4R5; R4 and R5 each independently represent hydrogen, alkyl or alkylcarbonyl; or R4 and R5 together with the nitrogen to which they are attached form an optionally substituted heterocyclic group; and the pharmaceutically acceptable salts thereof.
3. The method according to claim 2, wherein R\ represents -(CH2)m-A.
4. The method according to claim 2, wherein Ri and R2 both independently represent -(CH2)m-A.
5. The method according to claim 4 wherein A represents a substituted or unsubstituted C3.8 cycloalkyl group.
6. The method according to claim 4, wherein m represents 1.
7. The method according to claim 6, wherein A represents a substituted or unsubstituted cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl group.
8. The method according to claim 7, wherein A represents a cyclopropyl group or a cyclobutyl group.
9 The method according to claim 8, wherein R3 is nitro, or -NR4R5 wherein R4 is hydrogen and R5 is hydrogen or alkylcarbonyl
10 The method according to claim 9, wherein R4 or R5 is hydrogen
11 The method according to claim 10, wherein A represents a cyclopropyl group
12. The method according to claim 2 wherein the compound is selected from the group consisting of
1,3-di- - nn--bbuuttyyll--88--nniittrroo xxaanntthhiinnee,,
1,3-di- - ccyycclloopprrooppyyllmmeetthhyyll--88--nniittrroo xxaanntthhiirn ee,,
1,3-di- -c cyycclloobbuuttyyllmmeetthhyyll--88--nniittrroo xxaanntthhiinnee,
1,3-di- -c cyyccllooppeennttyyllmmeetthhyyll--88--nniittrroo xxaanntthhiinn ee,,
1,3-di- -c cyycclloohheexxyyllmmeetthhyyll--88--nniittrroo xxaanntthhiinnee,
1,3-di- -n n--bbuuttyyll--88--aammiinnoo xxaanntthhiinnee,,
1,3-di- -c cyycclloopprrooppyyllmmeetthhyyll--88--aammiinnoo xxaanntthhii nnee,,
1,3-di- -c cyycclloobbuutty3'llmmeetthhyyll--88--aammiinnoo xxaanntthhiinn ee,,
1 ,3-di- -c cyyccllooppeennttyyllmmeetthhyyll--88--aammiinnoo xxaanntthhiin nee,,
1,3-di- -c Dyycclloohheexxyyllmmeetthhyyll--88--aammiinnoo xxaanntthhiinn ee,,
1,3-di- -c :yycclloopprrooppyyll--88--aammiinnoo xxaanntthhiinnee,,
1,3-di- -n ╬╣--bbuuttyyll--88--aacceettaammiiddoo xxaanntthhiinnee,,
1,3-di- -╬╣n ╬╣--bbuuttyyll--88--cchhlloorroo xxaanntthhiinnee,,
1,3-di- -╬╣n ╬╣--bbuuttyyll--88--bbrroommoo xxaanntthhiinnee,, l,3-di- -<c ;yycclloopprrooppyyllmmeetthhyyll--88--cchhlloorroo xxaanntthhi mnee,, l,3-d╬╣- -(c ;yycclloohheexxyyll--88--cchhlloorroo xxaanntthhiinnee,,
1,3-di- -╬╣n ╬╣--bbuuttyyll--88--ppiippeerriiddiinnoo xxaanntthhiinnee,,
1,3-di- -cc ;yycclloopprrooppyyllmmeetthhyyll--88--mmoorφphhoolliinnoo > x caanntthhiinnee.,
1,3-di- -╬╣n ╬╣--bbuuttyyll--88--ppyyrrrroolliiddiinnyyll xxaanntthhiinnee,,
1,3-di- -cc :yycclloopprrooppyyllmmeetthhyyll--88--ppyyrrrroolliiddiinnyyll > x caanntthhiinnee,,
1,3-di- -cc :yycclloopprrooppyyllmmeetthhyyll--88--ppiippeeririddiinnyyll xx£a inntthhiinnee,,
1,3-di- -cc ;yycclloohheexxyyllmmeetthhyyll--88--ppiippeeririddiinnyyll xxaain itthhiinnee,,
1,3-di- -cc ;yycclloohheexxyyllmmeetthhyyll--88--bbrroommoo xxaanntthhiirn lee,, aanndd
1,3-di- -cc ;yycclloohheexxyyll--88--mmttrroo xxaanntthhiinnee,, oorr iiff a a pppprrooppririaattee,, aa D phhaarrmmΓêæa icceeuuttiiccaallllyy aacc ;cceeppttaabbllee salt thereof
13 The method according to Claim 2 wherein the compound is 1,3-di- cyclopropylmethyl-8-amino xanthine or a pharmaceutically acceptable salt thereof
14 The method of Claim 2 or 13 wherein the compound is administered orally, parenterally, topically or by inhalation
15 The method according to Claim 14 wherein the compound is administered topically
16 The method according to Claim 1 wherein the compound is administered topically with an effective amount of a second anti-pruritic compound
17 The method according to Claim 1 wherein the compound is described in WO 92/00968, PCT/US91/08229, WO 92/05175, WO 92/05176, WO
92/11260, WO 93/01014, PCT/US92/03613, WO 93/07111, PCT/US93/02045, WO 93/19748, WO 93/19750, WO 93/19751, WO 93/19747, WO 93/19749, WO 93/19720, WO 94/20079, WO 95/00139, WO 95/08581, WO 95/09308, WO 95/09623, WO 95/09836, WO 95/09624, WO 95/09837, WO 95/09627, WO 95/24381, WO 95/27692, WO 96/19995, WO 96/20158, WO 96/20153, WO 96/19980, WO 96/19988, WO96/19977, WO 96/20161, WO 96/20157, PCT/US95/ 16707, WO 96/20690, WO 96/20159, WO 96/19983, WO 96/19984, WO 96/19985, WO 96/19990, WO 96/19994, WO 96/20163, WO 96/20156, WO 96/19986, WO 96/20174, WO 96/19979, WO 96/20160 WO 96/20175, WO 96/19993, WO 96/20162, WO 96/19978, WO 96/23754, WO 96/36594, , WO 97/03945, US 5,734,051 and US 5,420, 154
18 A method of treating pruritis in a mammal in need thereof which comprises administering to such mammal an effective amount of the compound 1,3- di-cyclopropylmethyl-8-amino xanthine, or a pharmaceutically acceptable salt thereof
19 The method of Claim 18 wherein the compound is administered orally, parenterally, topically or by inhalation
20 The method according to Claim 19 wherein the compound is administered topically
21. The method according to Claim 18 wherein the compound is administered topically with an effective amount of a second anti-pruritic compound.
22. The method according to Claim 21 wherein the second anti-prutitic compound is a steroid.
EP98953608A 1997-10-17 1998-10-16 Novel use of compounds for anti-pruritic activity Withdrawn EP1030666A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6374697P 1997-10-17 1997-10-17
US63746P 1997-10-17
PCT/US1998/021886 WO1999020280A1 (en) 1997-10-17 1998-10-16 Novel use of compounds for anti-pruritic activity

Publications (2)

Publication Number Publication Date
EP1030666A1 true EP1030666A1 (en) 2000-08-30
EP1030666A4 EP1030666A4 (en) 2002-10-16

Family

ID=22051225

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98953608A Withdrawn EP1030666A4 (en) 1997-10-17 1998-10-16 Novel use of compounds for anti-pruritic activity

Country Status (18)

Country Link
EP (1) EP1030666A4 (en)
JP (1) JP2001520196A (en)
KR (1) KR20010031149A (en)
CN (1) CN1306426A (en)
AR (1) AR015966A1 (en)
AU (1) AU740875B2 (en)
BR (1) BR9814080A (en)
CA (1) CA2306985A1 (en)
CO (1) CO4810374A1 (en)
CZ (1) CZ20001376A3 (en)
HU (1) HUP0003792A3 (en)
IL (1) IL135581A0 (en)
NO (1) NO20001847D0 (en)
NZ (1) NZ503551A (en)
PL (1) PL341062A1 (en)
TR (1) TR200001040T2 (en)
WO (1) WO1999020280A1 (en)
ZA (1) ZA989450B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20031895A3 (en) 2001-01-31 2004-08-18 Pfizeráproductsáinc Nicotinamide biaryl derivatives useful as PDE4 isozyme inhibitors
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
PL365443A1 (en) 2001-01-31 2005-01-10 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
SK8942003A3 (en) 2001-01-31 2004-10-05 Pfizer Prod Inc Ether derivatives useful as inhibitors
US20030175314A1 (en) * 2001-11-19 2003-09-18 Didriksen Erik Johannes Pharmaceutical composition for dermal application
TW200503709A (en) * 2003-07-17 2005-02-01 Santen Pharmaceutical Co Ltd Itching treating agent containing piperidine derivative as active ingredient
WO2005053672A1 (en) * 2003-12-04 2005-06-16 Santen Pharmaceutical Co., Ltd. Remedy for pruritus comprising cilomilast or salt thereof as the active ingredient
JP2005187458A (en) * 2003-12-04 2005-07-14 Santen Pharmaceut Co Ltd Itchiness-treating agent consisting of cilomilast or its salt as active ingredient
EP1781657B1 (en) 2004-02-14 2013-03-27 GlaxoSmithKline Intellectual Property Development Limited Medicaments with hm74a receptor activity
JP2008137892A (en) * 2005-03-04 2008-06-19 Eisai Co Ltd Antipruritic agent
WO2007017261A1 (en) 2005-08-10 2007-02-15 Smithkline Beecham Corporation Xanthine derivatives as selective hm74a agonists
PL1992622T3 (en) 2006-02-21 2012-01-31 Eisai R&D Man Co Ltd 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative
TWI404709B (en) * 2006-02-21 2013-08-11 Eisai R&D Man Co Ltd 4-(3-benzamidophenyl) -6,7-dimethoxy-2-methylamine quinazoline derivatives
CA2678477A1 (en) 2007-02-16 2008-08-21 Eisai R&D Management Co., Ltd. Crystal, amorphous form and salt of methyl n-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl)phenyl]terephthalamic acid
JP5060561B2 (en) 2007-08-17 2012-10-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 New topical preparation
KR20100042245A (en) 2007-08-17 2010-04-23 에자이 알앤드디 매니지먼트 가부시키가이샤 Method for producing quinazoline derivative
EP2727594B1 (en) * 2011-06-28 2017-12-20 Mitsubishi Tanabe Pharma Corporation Naphtalene compounds to treat itch
BR112017016065A2 (en) 2015-01-30 2018-04-03 Shanton Pharma Co., Ltd. prevention or treatment of uric acid or gouty disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930703319A (en) * 1990-12-21 1993-11-29 데이빗 로버츠 Chianthine derivatives
ES2184077T3 (en) * 1996-03-26 2003-04-01 Altana Pharma Ag NEW FENANTRIDINS REPLACED IN POSITION 6.
JP2000510134A (en) * 1996-05-15 2000-08-08 ビイク グルデン ロンベルク ヒェーミッシェ ファブリーク ゲゼルシャフト ミット ベシュレンクテル ハフツング New imidazopyridine
JP2001514640A (en) * 1997-03-07 2001-09-11 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング New tetrazole
JP2002504091A (en) * 1997-03-18 2002-02-05 ベーアーエスエフ アクツィエンゲゼルシャフト Methods and compositions for modulating responsiveness to corticosteroids
SI0988302T1 (en) * 1997-06-03 2003-08-31 Altana Pharma Ag Benzonaphthyridines

Also Published As

Publication number Publication date
HUP0003792A3 (en) 2001-12-28
KR20010031149A (en) 2001-04-16
JP2001520196A (en) 2001-10-30
CO4810374A1 (en) 1999-06-30
NZ503551A (en) 2002-05-31
NO20001847L (en) 2000-04-10
CA2306985A1 (en) 1999-04-29
NO20001847D0 (en) 2000-04-10
IL135581A0 (en) 2001-05-20
CZ20001376A3 (en) 2002-06-12
HUP0003792A2 (en) 2001-10-28
EP1030666A4 (en) 2002-10-16
AU1093899A (en) 1999-05-10
PL341062A1 (en) 2001-03-26
BR9814080A (en) 2000-09-26
WO1999020280A1 (en) 1999-04-29
TR200001040T2 (en) 2001-01-22
AU740875B2 (en) 2001-11-15
AR015966A1 (en) 2001-05-30
ZA989450B (en) 1999-04-19
CN1306426A (en) 2001-08-01

Similar Documents

Publication Publication Date Title
AU740875B2 (en) Novel use of compounds for anti-pruritic activity
ES2214532T3 (en) USE OF DEXTRORPHAN OR DEXTROMETORPHAN FOR THE TREATMENT OF URINARY INCONTINENCE.
WO1999047131A2 (en) Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor
AU2012281042B2 (en) Combination ALS therapy
US6498173B1 (en) Synergistic combination comprising roflumilast and a pde-3 inhibitor
JPWO2006041121A1 (en) Treatment and / or prevention agent for chronic skin diseases
JPS625913A (en) Dihydropyridine-containing medicine
EP0345931B1 (en) Certain paf antagonist/antihistamine combinations and methods
HU183119B (en) Process for producing analgesic and tone-delivering compositions containing quinazoline derivatives and benzothiadiazol derivatives
WO1999047142A1 (en) Combination of a gaba-a alpha 5 inverse agonist and a nicotinic agonist
MXPA00003775A (en) Novel use of compounds for anti-pruritic activity
JPH0411526B2 (en)
JPH03215435A (en) Ulcer treatting agent containing aldose reductase inhibitor as main ingredient
AU4048800A (en) Viral treatment
JPS6245525A (en) Hypolipemic agent
GB1588095A (en) Composition for the treatment of scabies
AU1563902A (en) Novel use of compounds for anti-pruritic activity
EP0338010B1 (en) Pharmaceutical compositions for treatment of hyperproliferate skin disease
JPH09500648A (en) A method for inhibiting human immunodeficiency virus replication by substituted azaspirans.
AU5010193A (en) Methods of treating psoriasis employing substituted azaspiranes
JP2005533870A (en) Synergistic interaction of abaca beer and alovudine
JP2004026810A (en) Composition for rhinitis
JPH06211657A (en) Uric acid excretion agent
JPS625923A (en) Remedy for allergic disease
JPH04295427A (en) Gingivostomatitis therapeutic agent

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000508

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 20000508

A4 Supplementary search report drawn up and despatched

Effective date: 20020902

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040503